Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.
The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
Scientists map the genetic evolution of chronic lymphocytic leukemia (CLL) to Richter’s Syndrome.
Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.
The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.
Study clarifies molecular pathways by which CLL transform into a more aggressive type of lymphoma.
Wanda Zimmer, 66, a retired flight attendant, lives in Newport Beach, California. She has chronic lymphocytic leukemia (CLL).
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
Mark Hoffman, 57, who has chronic lymphocytic leukemia, learned how to ask a question that may have saved his life.
People with cancer not only are at increased risk for severe COVID-19, they also face treatment interruptions due to the pandemic.
The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
Doreen Zetterlund, 60, lives in Southern California. She has chronic lymphocytic leukemia.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
Brian Koffman, a family physician when diagnosed with chronic lymphocytic leukemia, cofounded the CLL Society.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.